SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (SHPH) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $200.72 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2026-03-31
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2025 was $200.72K, a 0.00% change from fiscal 2024.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2024 was $200.72K, a 44.36% decline from fiscal 2023.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2023 was $360.71K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|
| 2025-12-31 | $200.72K 10-K · filed 2026-03-31 |
| 2024-12-31 | $200.72K 10-K · filed 2025-02-26 |
| 2023-12-31 | $360.71K 10-K/A · filed 2024-09-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |